Triogem Asset Management's Tim Seymour looked to an Asian tech name.
"Baidu is the raging Chinese bull," he said. "And if the question is really, 'With 52-week highs for everything, what stock at a high right now would you buy?' Buy Baidu because you look at their second-quarter numbers, they're growing at 59 percent. They are monetizing mobile. They are also improving their margins."
In Seymour's "sell" column was utilities exchange-traded fund .
"I think the defensive nature of people looking to buy utilities for yield, etc., is going to start to fade," he said. "And I think in the second half you're going to see industrial growth that will make this much less interesting."
Trademonster's Pete Najarian said he saw an upward trajectory for Goldman Sachs.
"It actually right now is trading just over book value. I think it's going to accelerate into the end of the year because of all the deals that we're seeing happening," he said. "This is a company that's executing, and because of that, I think there's plenty of room to the upside."
Netflix, Najarian said, was a "sell."
"I love this name," he said. "I just think it's stretched. I think it's too much, too fast. It's up at $485 today. I think it actually pulls back somewhere near the 200-day moving average. That's the point to jump back in."
Stuart Frankel's Steve Grasso said that KB Home still looked strong.
"Now, it trades at 13 earnings. It trades at tangible book. The industry average is around 16 times," he said. "Plus, you've also heard me say about the deferred-tax asset. That comes on in November. It's going to start skewing as a cheap stock. It skews right now for quants as an expensive name. This one is going to run into year end."
Grasso put Exxon Mobil in the "sell" column.
"It's sitting right on its 200-day moving average, $98.30, basically," he said. "Now, if crude continues to move lower, then this one will move lower as well. I'm just worried about that move in crude, might be a little bit overdone. And I think you have to hope for unseasonably warm weather going into September/October."
Private Advisor Group's Guy Adami's "buy" pick was Celgene.
"Biotech is not in a bubble despite what people say," he said. "Nineteen times forward earnings is not expensive for these guys. They have an unbelievable balance sheet. They dominate in a number of different areas. They have a great management team. This is a stock that we've talked about forever. It's at an all-time high with the S&P. I think it goes higher from here."
Adami said he would ditch—but not short—Home Depot due to its quick run-up from $82 to $92.
"But how much better can it possibly get into next quarter? I think you sell it here," he said. "You look for a pullback back down to $84, and then you buy it again."
—By CNBC's Bruno J. Navarro